Loading the section…

WGS: financial statements from SEC — TradeAlmanac

WGS

GeneDx Holdings Corp.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	102M	117M	103M	87M	77M	71M
Cost of revenue	34M	32M	32M	29M	29M	28M
Gross profit	68M	85M	71M	58M	48M	43M
Research and development	20M	20M	15M	13M	12M	11M
Selling, general and administrative	75M	44M	27M	32M	27M	26M
Operating income	−57M	−3M	9M	−5M	−8M	−11M
Pre-tax income	−62M	−7M	11M	−6M	−8M	−29M
Income tax	897,000	247,000	−246,000	447,000	−47,000	−190,000
Net income	−63M	−8M	11M	−7M	−8M	−29M
Earnings per share	−2.16	−0.27	0.38	−0.23	−0.31	−1.10
Earnings per share, diluted	−2.16	−0.27	0.36	−0.23	−0.31	−1.10
Weighted average shares	29M	29M	29M	28M	27M	27M
Weighted average shares, diluted	29M	29M	30M	28M	27M	27M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	94M	105M	96M	74M	100M	85M	59M	57M
Short-term investments	77M	66M	59M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−32M	10M
Depreciation and amortisation	7M	6M
Share-based compensation	9M	4M
Capital expenditure	6M	6M
Investing cash flow	−17M	−9M
Financing cash flow	39M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator